ArticlePhysical biology2011
The role of carrier number on the procoagulant activity of tissue factor in blood and plasma.
Article in Physical biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- Exploring the Emerging Association Between Immune Checkpoint Inhibitors and Thrombosis.Journal of clinical medicine · 2025Review
- Evaluation of the Antihemostatic and Antithrombotic Effects of Lowering Coagulation Factor VII Levels in a Non-human Primate.Cellular and molecular bioengineering · 2020Article
- Biorheology of platelet activation in the bloodstream distal to thrombus formation.Cellular and molecular bioengineering · 2016Article
- Expression of tissue factor and forkhead box transcription factor O-1 in a rat model for chronic thromboembolic pulmonary hypertension.Journal of thrombosis and thrombolysis · 2016Article
- The role of tissue factor and autophagy in pulmonary vascular remodeling in a rat model for chronic thromboembolic pulmonary hypertension.Respiratory research · 2016Article
- The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation.American journal of physiology. Cell physiology · 2015Article
- Physical biology in cancer. 2. The physical biology of circulating tumor cells.American journal of physiology. Cell physiology · 2014Review
- Expression of tissue factor in rabbit pulmonary artery in an acute pulmonary embolism model.World journal of emergency medicine · 2014Article
- Phosphatidylserine index as a marker of the procoagulant phenotype of acute myelogenous leukemia cells.Physical biology · 2013Article
- Physiological levels of blood coagulation factors IX and X control coagulation kinetics in an in vitro model of circulating tissue factor.Physical biology · 2013Article
- Article
- Microfluidics and coagulation biology.Annual review of biomedical engineering · 2013Review
- Do circulating tumor cells play a role in coagulation and thrombosis?Frontiers in oncology · 2012Article
- Modeling and simulation of procoagulant circulating tumor cells in flow.Frontiers in oncology · 2012Article
- Development of coagulation factor probes for the identification of procoagulant circulating tumor cells.Frontiers in oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Tissue factor (TF) is a transmembrane glycoprotein cofactor of activated blood coagulation factor VII (FVIIa) that is required for hemostatic thrombin generation at sites of blood vessel injury. Membrane-associated TF detected in circulating blood of healthy subjects, referred to as intravascular or circulating TF has been shown to contribute to experimental thrombus propagation at sites of localized vessel injury. Certain disease states, such as metastatic cancer, are associated with increased levels of intravascular TF and an elevated risk of venous thromboembolism. However, the physiological relevance of circulating TF to hemostasis or thrombosis, as well as cancer metastasis, is ill-defined. This study was designed to assess whether the spatial separation of intravascular TF carriers in blood, demonstrated with TF-inducible human monocytic cell line U937 or TF-coated polymer microspheres, affected procoagulant activity and hence thrombogenic potential. Experiments were performed to characterize the effects of TF-carrier number on the kinetics of clot formation in both open and closed systems. The procoagulant activity of TF carriers was found to correlate with spatial separation in both closed, well-mixed systems and open, flowing systems. TF carriers enhanced the amidolytic activity of FVIIa toward the chromogenic substrate, S-2366, as a function of carrier count. These results suggest that TF-initiated coagulation by circulating TF is kinetically limited by mass transport of TF-dependent coagulation factors to the TF-bearing surface, a constraint that may be unique to circulating TF. Spatial separation of circulating TF carriers is therefore a critical determinant of the procoagulant activity of circulating TF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.